SEC Form 4 · accession 0000921895-18-002804
Enveric Biosciences, Inc. · ENVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Kostiner
Officer — Chief Financial Officer
Period of report
Oct 17, 2018
Accepted (ET)
Oct 19, 2018 · 4:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000890821
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (Right to Buy)F1 | $1.13 | Oct 17, 2018 | A | 150,000 | A | Oct 17, 2019 | Oct 17, 2023 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The Option vests as follows: (a) as to 50,000 shares of common stock of the Issuer ("Stock"), on October 17, 2019, (b) as to a further 50,000 shares of common stock on October 17, 2020 and (c) as a further 50,000 shares of common stock on October 17, 2021.